COPIKTRA decreased the risk of progression in nearly all analyzed high-risk patient subgroups3
*
Kaplan-Meier estimate
CI, confidence interval; CLL, chronic lymphocytic leukemia; HR, hazard ratio; ITT, intention to treat; SE, standard error; SLL, small lymphocytic lymphoma.
